Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.60 |
| ▸ | ADAMTS4 | O75173 | 8/20 | 0.60 |
| ▸ | MMP1 | P03956 | 15/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204159 | 0.94 | MMP1 (0.60) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7203221 | 0.91 | MMP13 (0.59) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7205398 | 0.90 | MMP13 (0.58) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7201681 | 0.89 | MMP13 (0.59) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7203200 | 0.88 | MMP1 (0.58) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7207909 | 0.85 | MMP13 (0.54) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7202550 | 0.85 | MMP1 (0.58) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7205413 | 0.84 | MMP1 (0.57) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7201597 | 0.83 | MMP13 (0.60) | MMP13ADAMTS4MMP1ADAM17MMP2 | |
| SCHEMBL7206979 | 0.82 | MMP13 (0.71) | MMP13ADAMTS4MMP1ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP13 4/4885ADAMTS4 26/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.